Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/1538-7445.am2022-ct559
Abstract: Background: MET amplification can arise as a bypass resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) and occurs in ~5-26% of EGFR TKI resistant EGFR-mutant non-small cell lung cancer (NSCLC). These patients (pts) have limited… read more here.
Keywords: egfr mutant; capmatinib; osimertinib platinum; egfr ... See more keywords